Emerging as a noteworthy breakthrough in the battle against obesity, this medication is capturing considerable interest . It combines the action of two known GLP-1 binding agonists, liraglutide, with an unique glucose-dependent incretin component. Initial study data have indicated substantial body reduction in individuals with excessive weight, pot